A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is to evaluate the safety, biodistribution, radiation dosimetry and tumor uptake of the \[68Ga\]/ \[131I\]-IR199 in patients with Claudin 18.2 positive gastric cancer and pancreatic cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzona diagnosis raka żołądka lub trzustki z obecnością białka Claudin 18.2
- •Co najmniej jedno widoczne ognisko nowotworu dodatnie na białko Claudin 18.2
- •Pisemna zgoda pacjenta lub jego przedstawiciela prawnego
✗ Disqualifies
- •Leczenie w ciągu ostatnich dwóch tygodni, które mogło osłabić układ krwiotwórczy
- •Poważne problemy z nerkami lub układem moczowym (stopień 3 lub wyższy)
- •Uczulenie lub nietolerancja na leki radioaktywne
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Huashan Hospital
Shanghai, China
Trial contact
Yihui Guan, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.